(Source: GSK - GlaxoSmithKline plc) PRESS RELEASE ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen Studies will investigate monthly dosing with injectable cabotegravir and rilpivirine London, UK, 18 November 2016-ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the start of two phase III studies designed to evaluate an investigational long-acting, injectable regimen of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen Sciences Ireland UC) for the treatment of HIV-1 infection. The two studies, FLAIR (First Long-Acting Injectable Regimen)...
↧